ライフサイエンスコーパス: antiangiogenic

1 recent data suggesting that the efficacy of antiangiogenic (AA) therapies is limited in some circums

2 for the anti-inflammatory, antiscarring, and antiangiogenic actions of the AM.

3 neration ITZ analogues for their anti-Hh and antiangiogenic activities to probe more fully the struct

4 oteinase inhibitor (SERPIN) superfamily with antiangiogenic activities, were elevated in type 2 diabe

5 CSF) level in the EDM-TTF-1(+) conferred the antiangiogenic activities.

6 nase (FAK) have been recently shown to exert antiangiogenic activity against HUVEC cells and anticanc

7 lampsia (PE), which have proinflammatory and antiangiogenic activity and are implicated in PE pathoph

8 However, its potent antiangiogenic activity and the molecular targets of alp

9 from Aspergillus fumigatus, is known for its antiangiogenic activity due to binding to human methioni

10 Remarkably, VEGF-Ax exhibits antiangiogenic activity in contrast to the proangiogenic

11 lead compound was then evaluated in vivo for antiangiogenic activity in the CAM model and in a xenogr

12 this step were then screened to isolate the antiangiogenic activity in vitro.

13 validation and mechanistic definition of the antiangiogenic activity of a novel mycotoxin, with poten

14 The antiangiogenic activity of alpha1(IV)NC1 is mediated, in

15 gth forms could also counter balance the pro/antiangiogenic activity of each other in in vitro angiog

16 reover, our data reveal that the established antiangiogenic activity of protamine would rely on APJ a

17 dues on the affinity, anti-inflammatory, and antiangiogenic activity of these azapeptides have now be

18 designed, synthesized, and tested for their antiangiogenic activity using in vitro assays with human

19 rgets and their effects on metformin-induced antiangiogenic activity were assessed using luciferase a

20 ylase inhibitor) via an ester bond, exhibits antiangiogenic activity, being able to reduce human reti

21 Remarkably, VEGF-Ax exhibits potent antiangiogenic activity, both in vitro and in vivo, thus

22 ta-D-glucopyranose) is a CMG2 inhibitor with antiangiogenic activity.

23 mination of the response to therapy with the antiangiogenic agent axitinib, a multiple receptor tyros

24 a standard clinical treatment course of the antiangiogenic agent sunitinib.

25 proval of an anti-VEGF antibody as the first antiangiogenic agent, many patients with cancer and ocul

26 C single-arm studies that did not include an antiangiogenic agent.

27 iled to show an overall survival benefit for antiangiogenic agents alone or in combination with chemo

28 ay be a unique target in situations in which antiangiogenic agents are withdrawn, and dual targeting

29 understanding of the mechanisms of action of antiangiogenic agents has hindered optimization and broa

30 Antiangiogenic agents have established efficacy in the t

31 These results indicate that antiangiogenic agents may not be beneficial in unselecte

32 ombined therapy with a FAK inhibitor and the antiangiogenic agents pazopanib and bevacizumab reduced

33 es that the most efficacious applications of antiangiogenic agents rely upon a combination with cytot

34 r current antiangiogenic therapies, as these antiangiogenic agents target normal vasculature as well

35 The potential to heighten the efficacy of antiangiogenic agents was explored in this study based o

36 motherapy and radiotherapy), targeted drugs, antiangiogenic agents, and immunotherapy, including chec

37 Further research with novel antiangiogenic agents, particularly in the maintenance s

38 ing in single-arm phase 2 studies evaluating antiangiogenic agents, this risk for all events (OR 4.34

39 oting effective subsequent therapy including antiangiogenic agents.

40 st experience of maintenance therapy is with antiangiogenic agents.

41 stoma has been the therapeutic evaluation of antiangiogenic agents.

42 using lower "vascular normalizing" doses of antiangiogenic agents.

43 hemorrhage in patients with HCC treated with antiangiogenic agents.

44 s well as a factor in guiding treatment with antiangiogenic agents.

45 o those of continuous treatment with various antiangiogenic agents.

46 Sunitinib maintained its antiangiogenic and antimetastatic activity but lost its

47 s between M1-type polarized macrophages with antiangiogenic and antitumor activity and M2-type polari

48 of a lead candidate (6z) that combined both antiangiogenic and antitumoral effects.

49 itargeted tyrosine kinase inhibitor that has antiangiogenic and antitumorigenic properties with poten

50 ng of endothelial FABP4 by siRNA in vivo has antiangiogenic and antitumour effects with minimal toxic

51 lial Stat3 ablation led to a shift toward an antiangiogenic and axon growth-inhibiting micromilieu af

52 We evaluated the effects of combined antiangiogenic and chemotherapy treatments on advanced s

53 antiangiogenic protein, can activate latent antiangiogenic and proangiogenic sites, respectively.

54 CD36 and exhibited respectively significant antiangiogenic and slight angiogenic activities in a mic

55 rom 1997 to 2006; 12 of those studies tested antiangiogenic and/or anti-epidermal growth factor recep

56 ich suggests no positive interaction between antiangiogenics and tyrosine kinase inhibitors in the tr

57 xin from a novel source that exhibits potent antiangiogenic antitumor activity.

58 Antiangiogenic approaches that have shown benefit in oth

59 Our data demonstrate that miR-155 exerts an antiangiogenic but proarteriogenic function in the regul

60 genesis, and have conceptual implication for antiangiogenic cancer therapy.

61 e drugs that might also bypass the so-called antiangiogenic ceiling and have led to selective treatme

62 ations for the redox-mediated release of the antiangiogenic cleavage product from HRG.

63 Further, we analyzed antiangiogenic components in RAC exosomes using an angio

64 effects, with exosomes from RACs containing antiangiogenic components that might protect the eye fro

65 In this work, we describe a new antiangiogenic compound (22) that inhibits proangiogenic

66 n five analogues of a clinically established antiangiogenic compound (sunitinib), from which a lead c

67 and erlotinib emerge as attractive candidate antiangiogenic compounds for prevention and treatment of

68 ovide a rationale for the development of new antiangiogenic compounds that could eventually lead to n

69 cells, turning them into dual cytotoxic and antiangiogenic compounds.

70 essing the presence of tumor vasculature and antiangiogenic drug activity.

71 In summary, Q8 is a more effective antiangiogenic drug compared with quininib.

72 nvasive imaging biomarker of response to the antiangiogenic drug sunitinib.

73 Tasquinimod is an orally active antiangiogenic drug that is currently in phase III clini

74 In addition, sorafenib is described as an antiangiogenic drug, but it also acts on immunological c

75 ort for the concept that ENOX1 represents an antiangiogenic druggable target.

76 toxins exert increased toxicity compared to antiangiogenic drugs and may therefore overcome these li

77 Bevacizumab is one of the most widely used antiangiogenic drugs in oncology, but the overall benefi

78 Targeted treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inh

79 oma metastasis occurs at the early stage and antiangiogenic drugs such as Vegf morpholino and sunitin

80 Ten antiangiogenic drugs targeting VEGF or its receptors are

81 However, the ability of antiangiogenic drugs to delay tumor progression and exte

82 ab, highlighting the need for more effective antiangiogenic drugs with novel mechanisms of action.

83 However, antiangiogenic drugs, peptide receptor radionuclide ther

84 VEGF pathway-targeting antiangiogenic drugs, such as bevacizumab, when combined

85 well tolerated in children, with evidence of antiangiogenic effect and potential clinical benefit in

86 giogenesis during therapy, despite a greater antiangiogenic effect of bevacizumab, such that a revers

87 hile p56/Lck short hairpin RNA inhibited the antiangiogenic effect of HKa.

88 The antiangiogenic effect of PRP was analysed by matrigel-ba

89 erved owing to the enhanced photothermal and antiangiogenic effect of RDLPNPs.

90 autophagy, an antitumor immune response, an antiangiogenic effect, and a significant "bystander" ant

91 mpair periodontal tissue repair, despite its antiangiogenic effect.

92 doses of type I IFNs occurs through a direct antiangiogenic effect.

93 VEGF-A signaling, whereas IFNgamma shows an antiangiogenic effect.

94 Q8 elicits antiangiogenic effects in a VEGF-independent in vitro mo

95 that miR-146a is a critical mediator of the antiangiogenic effects in endothelial cells.

96 oxides 17,18-EEQ-EA and 19,20-EDP-EA exerted antiangiogenic effects in human microvascular endothelia

97 This suggests that local CsA has negligible antiangiogenic effects in the human cornea, at least in

98 receptor kinase inhibitor SU5416, increased antiangiogenic effects in vitro and in a zebrafish angio

99 We found that ANGPTL7 itself has strong antiangiogenic effects in vitro.

100 of VEGF by bevacizumab explain the additive antiangiogenic effects observed in combination with Q8.

101 an endothelial tube assay and attenuated the antiangiogenic effects of sFlt1.

102 Mechanistically, the antiangiogenic effects of sorafenib led to increased bon

103 epleting intracerebral copper, also exhibits antiangiogenic effects on brain tumor growth in mice.

104 The results showed that miR-499 had antiangiogenic effects on the HUVECs and suppressed the

105 imizing efficacy of chemotherapeutic agents, antiangiogenic effects, and altering antitumor immunity.

106 f thalidomide, an immunomodulatory drug with antiangiogenic effects, is limited by its toxicity.

107 tion of specific antimitotic and nonspecific antiangiogenic effects.

108 expression, alveolar cell apoptosis, and the antiangiogenic factor GAX, and decreased expression of H

109 ng in the tumor microenvironment through the antiangiogenic factor IGFBP5.

110 factor-binding protein 5 (IGFBP5), a potent antiangiogenic factor implicated in tumor suppression.

111 factor and later as the most potent natural antiangiogenic factor, a stem cell niche factor, and an

112 (MMP)-14 at the cell surface to release the antiangiogenic factor, soluble endoglin (sEng).

113 is associated with overexpression of a novel antiangiogenic factor, VEGF-A165b, that may play a patho

114 We show that the ratio of pro/antiangiogenic forms of CgA is altered in multiple myelo

115 ogenous CXCL4L1, which is independent of its antiangiogenic function.

116 hemokine that has been suggested to exert an antiangiogenic function.

117 l of SH-11037, a synthetic derivative of the antiangiogenic homoisoflavonoid cremastranone, in models

118 Our trials of antiangiogenics in patients with newly diagnosed and rec

119 this study, we examined the role of a novel antiangiogenic isoform of vascular endothelial growth fa

120 etic (c(AmpRGD)) and the clinically approved antiangiogenic kinase inhibitor sunitinib, three novel d

121 These results indicate that miR-223 is an antiangiogenic microRNA that prevents endothelial cell p

122 methylation leading to induced expression of antiangiogenic miR-221 by GATA2-dependent demethylation

123 t the combination of PTX-loaded NPs with the antiangiogenic molecular inhibitor BIBF 1120 (BIBF) prom

124 ental evidence that K5-N,OS(H) represents an antiangiogenic multitarget molecule with potential impli

125 ere scanned before and 24 hours after either antiangiogenic (n = 9) or saline-only (n = 8) treatment.

126 ell (HUVECs) proliferation, indicating their antiangiogenic nature.

127 ninib analogues and identified a more potent antiangiogenic novel chemical entity (IUPAC name (E)-2-(

128 This study showed that antiangiogenic or corticosteroid intravitreal treatment

129 njugation of SAN1 did not disrupt any of its antiangiogenic or cytotoxic properties in GnRH-R-express

130 cificity, and has no detectable teratogenic, antiangiogenic or neurotoxic effects at potent anti-infl

131 Tumor growth was inhibited after antiangiogenic or radiation therapy.

132 ial of these tracers to monitor responses of antiangiogenic or radiation therapy.

133 Novel combinations of these drugs with other antiangiogenics or other classes of drugs are being deve

134 tiangiogenic therapy, and highlight emerging antiangiogenic paradigms.

135 These studies reveal a SHP-1-mediated antiangiogenic pathway induced by CD36-TSP-1 interaction

136 nd metastasis by catalyzing the formation of antiangiogenic peptides.

137 and underlie escape mechanisms from current antiangiogenic pharmacotherapies.

138 is a novel tumor suppressor that induces an antiangiogenic phenotype and suppresses tumor growth, in

139 ith increased endothelial cell apoptosis, an antiangiogenic plasma profile, and elevated levels of ci

140 orts the idea that Akt can be either pro- or antiangiogenic, possibly due to compensation by multiple

141 embryo angiogenesis assay again confirms the antiangiogenic properties of 1 and 4.

142 , a proteasome inhibitor with anticancer and antiangiogenic properties used in the clinic for treatme

143 st because of their unique antimigration and antiangiogenic properties.

144 n of the protease activated receptor-1, with antiangiogenic properties.

145 ate for oxylipins with anti-inflammatory and antiangiogenic properties.

146 le Fms-like tyrosine kinase-1 (sFlt-1) is an antiangiogenic protein believed to mediate the signs and

147 s analyses in endothelial cells returned the antiangiogenic protein thrombospondin-1 as a common targ

148 g chromogranin A (CgA, CHGA), classically an antiangiogenic protein, can activate latent antiangiogen

149 ike tyrosine kinase 1 (sFlt1), a circulating antiangiogenic protein, is elevated in kidney diseases a

150 ike tyrosine kinase 1 (sFLT1), a circulating antiangiogenic protein, precede clinical signs and sympt

151 pigment epithelium-derived factor (PEDF), an antiangiogenic protein, to regulate retinal pigment epit

152 Our results unravel specific features of antiangiogenic resistance, with potential therapeutic im

153 dependent activity coupled with the additive antiangiogenic response observed in combination with bev

154 conclusion, SC-MRI enabled monitoring of the antiangiogenic response of 786-0 RCC xenografts to sunit

155 model of angiogenesis and exerts an additive antiangiogenic response with the anti-VEGF biologic beva

156 Given that VEGF can elicit both pro- and antiangiogenic responses depending upon the balance of s

157 ner, while most other semaphorins, including antiangiogenic semaphorins such as sema3A do not.

158 servations suggest that elevated circulating antiangiogenic serpins in diabetic patients may contribu

159 dothelial cells and to induce either pro- or antiangiogenic signaling.

160 We reported earlier the delivery of antiangiogenic single chain antibodies by using oncolyti

161 Previous studies discovered quininib, an antiangiogenic small molecule antagonist of cysteinyl le

162 the mechanism of resistance to sunitinib, an antiangiogenic small molecule, and to exploit this mecha

163 ased assay that responds to complex pro- and antiangiogenic soluble factors with an in vitro readout

164 In tumors, antiangiogenic, specifically anti-VEGF, treatments can "

165 egrowth in PAD to increased expression of an antiangiogenic splice variant of VEGF-A.

166 ated by GATA2 transcriptionally and targeted antiangiogenic SPRED1 and FOXO3a contributing to GATA2-m

167 rogram lung cancer secreted proteome into an antiangiogenic state, offering a novel basis to account

168 se findings might pave the way toward novel, antiangiogenic strategies in disorders that are characte

169 Currently, antiangiogenic strategies in metastatic breast cancer ha

170 tomised treatment, which should increase the antiangiogenic survival ceiling.

171 cytes may represent a novel, nonendothelial, antiangiogenic target for lymphoma therapy.

172 Inhibition of p110alpha may thus offer a new antiangiogenic therapeutic opportunity in cancer.

173 otential target for the development of novel antiangiogenic therapeutics, and blockade of its product

174 cular tumors are not a known complication of antiangiogenic therapeutics.

175 ools with which to easily evaluate potential antiangiogenic therapies beyond eye research.

176 Successful antiangiogenic therapies have been developed for the tre

177 Antiangiogenic therapies have failed to confer survival

178 Antiangiogenic therapies like bevacizumab offer promise

179 ing strategies of combinations of immune and antiangiogenic therapies may lead to further advancement

180 eted therapy (radiation/chemo) together with antiangiogenic therapies reduced GBM tumor size but incr

181 Antiangiogenic therapies show some therapeutic potential

182 onse and nonenhancing tumor progression from antiangiogenic therapies, and pseudoprogression from rad

183 naling remains a major challenge for current antiangiogenic therapies, as these antiangiogenic agents

184 However, rapid emergence of resistance to antiangiogenic therapies, such as bevacizumab, greatly l

185 Antiangiogenic therapies, such as sunitinib, have revolu

186 ve of this study was to evaluate alternative antiangiogenic therapies, which target multiple VEGF fam

187 , age, tumor type and involvement, and prior antiangiogenic therapies.

188 allow for an improved response assessment to antiangiogenic therapies.

189 oit this seminal pathway and improve current antiangiogenic therapies.

190 s that affect vascular permeability, such as antiangiogenic therapies.

191 sent in GSC and are resistant to traditional antiangiogenic therapies.

192 s, and the potential activity of alternative antiangiogenic therapies.

193 Antiangiogenic therapy (AAT) is a treatment option that

194 RC-52 xenografts after treatment with either antiangiogenic therapy (bevacizumab or sorafenib) or tum

195 Antiangiogenic therapy also selects for aggressive pheno

196 erlying mechanisms of resistance specific to antiangiogenic therapy and develop strategies to overcom

197 gs challenge both the original rationale for antiangiogenic therapy and our understanding of the phys

198 Tumors escape antiangiogenic therapy by activation of proangiogenic si

199 e effect and to potentiate responsiveness to antiangiogenic therapy by concomitantly targeting ECM-mo

200 ndings offer strong evidence that short-term antiangiogenic therapy can promote a transient vessel no

201 g laser photocoagulation, vitrectomy, and/or antiangiogenic therapy confirmed by an external adjudica

202 as the potential to be manipulated in future antiangiogenic therapy design.

203 Despite clear antitumor efficacy, antiangiogenic therapy did not alter tumor uptake of (11

204 Antiangiogenic therapy effects were detected earlier and

205 In this context, antiangiogenic therapy emerged as a promising treatment

206 ctions of RAC exosomes, we might improve the antiangiogenic therapy for CNV in age-related macular de

207 ew challenge for uninterrupted and sustained antiangiogenic therapy for treatment of human cancers.

208 Sunitinib is an antiangiogenic therapy given as a first-line treatment f

209 Antiangiogenic therapy has shown clear activity and impr

210 ma is a highly vascularized brain tumor, and antiangiogenic therapy improves its progression-free sur

211 jor role for Gal-1 as a tractable target for antiangiogenic therapy in advanced stages of the disease

212 Resistance to antiangiogenic therapy in glioblastoma (GBM) patients ma

213 The role of antiangiogenic therapy in mCRPC remains investigational.

214 The efficacy of antiangiogenic therapy in neovascular AMD is strongly de

215 c (CT) images, and predict tumor response to antiangiogenic therapy in patients with metastatic renal

216 However, current antiangiogenic therapy induces serious adverse effects i

217 Antiangiogenic therapy is efficacious in metastatic rena

218 Intravitreal antiangiogenic therapy is the major therapeutic breakthr

219 tumor vessel numbers and function following antiangiogenic therapy may also affect intratumoral deli

220 tic that complements and improves concurrent antiangiogenic therapy may be a promising treatment stra

221 In conclusion, tumor perfusion changes after antiangiogenic therapy may distinguish responders vs. no

222 Prudent antiangiogenic therapy might transiently normalize blood

223 eflects the viability of tumor tissue during antiangiogenic therapy more reliably than contrast-enhan

224 ation of the blood-brain barrier (BBB) after antiangiogenic therapy of gliomas with bevacizumab may r

225 In particular, the impact of antiangiogenic therapy on tumor blood flow and oxygenati

226 decade and propose strategies for improving antiangiogenic therapy outcomes for malignant and nonmal

227 Bevacizumab is the first antiangiogenic therapy proven to slow metastatic disease

228 The mechanisms of resistance to antiangiogenic therapy remain incompletely understood.

229 Antiangiogenic therapy resistance occurs frequently in p

230 junctive CXCR4 antagonists may help overcome antiangiogenic therapy resistance, benefiting GBM patien

231 etabolic traits of tumors can be selected by antiangiogenic therapy suggests insights into the evolut

232 Thus, beta1 integrins promote resistance to antiangiogenic therapy through potentiation of multiple

233 sion of this molecule is an ideal target for antiangiogenic therapy to treat cancer.

234 Antiangiogenic therapy with antibodies against VEGF (bev

235 nitor response of colon cancer xenografts to antiangiogenic therapy with functional and molecular US

236 f disease manifestations and is a target for antiangiogenic therapy with the monoclonal antibody beva

237 tient management and monitor the response to antiangiogenic therapy with the optimum noninvasive imag

238 rgeting pBMDC influx along with radiation or antiangiogenic therapy would be critical to prevent vasc

239 discuss successes and challenges of current antiangiogenic therapy, and highlight emerging antiangio

240 infiltration into tumors after withdrawal of antiangiogenic therapy, and lowering platelet counts mar

241 on factors were selected chemotherapy, prior antiangiogenic therapy, and platinum-free interval.

242 ikely reflects an onset of hypoxia caused by antiangiogenic therapy, and that beta1 inhibition is wel

243 r SK-RC-52 xenografts was not affected after antiangiogenic therapy, except in head and neck squamous

244 ncer that responds to checkpoint blockade or antiangiogenic therapy, uncovering a protective role by

245 These include antiangiogenic therapy, vasodilatory agents, antilymphog

246 e absence of VEGF, following radiotherapy or antiangiogenic therapy, we documented an increase in Ang

247 redict which mRCC patients will benefit from antiangiogenic therapy.

248 ted negative effects following withdrawal of antiangiogenic therapy.

249 th treatment-naive BCVA and BCVA outcomes in antiangiogenic therapy.

250 with clear-cell mRCC previously treated with antiangiogenic therapy.

251 inhibited tumor rebound after withdrawal of antiangiogenic therapy.

252 nal measurement of ovarian tumor response to antiangiogenic therapy.

253 t to Nck as an emergent target for effective antiangiogenic therapy.

254 ve outcomes of patients with GBM who receive antiangiogenic therapy.

255 assessment of early treatment response after antiangiogenic therapy.

256 with Angpt/Tie2 has the potential to improve antiangiogenic therapy.

257 e an antitumor agent and open a new field of antiangiogenic therapy.

258 es is not necessarily decreased by effective antiangiogenic therapy.

259 2 followed tumor volume in studies featuring antiangiogenic therapy.

260 ectively block tumor progression and improve antiangiogenic therapy.

261 orafenib might be a ceiling for single-agent antiangiogenic therapy.

262 rtance, VEGF has been at the center stage of antiangiogenic therapy.

263 g responses to anticancer therapy, including antiangiogenic therapy.

264 herapies, especially for tumors treated with antiangiogenic therapy.

265 sociated with increased expression levels of antiangiogenic thrombospondin-1 and inhibited S1177 phos

266 h factor]), and an increase in the levels of antiangiogenic (TNFalpha [tumor necrosis factor alpha],

267 ere randomized to receive either single-dose antiangiogenic treatment (bevacizumab, n = 14) or contro

268 optimized vision outcomes by combination of antiangiogenic treatment and vaso-occlusive PDT.

269 doxycycline could be used to enhance current antiangiogenic treatment approaches in various condition

270 icantly decreased (P </= .03) after a single antiangiogenic treatment compared with those in the cont

271 g nontargeted microbubbles for assessment of antiangiogenic treatment effects in a murine model of hu

272 nd functional in vivo imaging information on antiangiogenic treatment effects in human colon cancer x

273 to diagnose tumor progression and to assess antiangiogenic treatment effects.

274 s needed regarding safety, dose, and type of antiangiogenic treatment for ROP.

275 d the effect of a preventive and therapeutic antiangiogenic treatment in a diet-induced mouse model f

276 T tracer, in mRCC patients before and during antiangiogenic treatment in a pilot study.

277 No validated predictive biomarkers for antiangiogenic treatment of metastatic renal cell carcin

278 also reveal molecular mechanisms underlying antiangiogenic treatment resistance, suggesting potentia

279 modeling reveals a more detailed response to antiangiogenic treatment than a single static image is a

280 Individualization of antiangiogenic treatment using data from clinical trials

281 ious disciplines, most prominently including antiangiogenic treatment with bevacizumab.

282 indicate that not all patients benefit from antiangiogenic treatment, necessitating the development

283 ization in eyes receiving recurrent periodic antiangiogenic treatment.

284 ght serve as a tool to stratify patients for antiangiogenic treatment.

285 sels (P = .03) significantly decreased after antiangiogenic treatment.

286 nducible factor-1alpha (HIF1alpha) caused by antiangiogenic treatment.

287 s model highlight the risks of cytotoxic and antiangiogenic treatments in the context of tumor hetero

288 e way for the clinical approval of the first antiangiogenic tumor drug 15 years later.

289 h is involved in mechanisms of resistance to antiangiogenic tumour therapy.

290 e in a murine model of mBC resistance to the antiangiogenic tyrosine kinase inhibitor sunitinib.

291 Antiangiogenic tyrosine kinase inhibitors (TKI) that tar

292 Cediranib is an oral antiangiogenic vascular endothelial growth factor recept

293 reduced expression of pro-angiogenic but not antiangiogenic VEGF isoforms.

294 e that inflammation-driven expression of the antiangiogenic VEGF-A isoform can contribute to impaired

295 PAD is associated with elevated levels of an antiangiogenic VEGF-A splice isoform (VEGF-A165b) and a

296 In contrast, in the BS, melatonin releases antiangiogenic VEGF-Axxxb from the PT, inhibiting infund

297 65a, 165 for the 165 amino acid product) and antiangiogenic VEGFxxxb (VEGF165b) isoforms.

298 The antiangiogenic VEGFxxxb isoforms are thought to antagoni

299 d rBF significantly decreased (P </= .04) in antiangiogenic versus saline-treated tumors.

300 the possible beneficial effects of combining antiangiogenic with tumor-specific immunotherapeutic app